Immune checkpoint blockade therapy for esophageal squamous cell carcinoma

Kazuto Harada^{1

2}, Dilsa Mizrak Kaya¹, Hideo Baba², Jaffer A Ajani¹

Affiliations

¹ Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd, Houston, TX 77030, USA.
² Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto 860-8556, Japan.

Editorial

Kazuto Harada et al. J Thorac Dis. 2018 Feb.

. 2018 Feb;10(2):699-702.

doi: 10.21037/jtd.2018.01.120.

Kazuto Harada^{1

2}, Dilsa Mizrak Kaya¹, Hideo Baba², Jaffer A Ajani¹

¹ Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd, Houston, TX 77030, USA.
² Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto 860-8556, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Need for prospective collection of experience and repeated samples in esophageal squamous cell carcinoma.
Hamamoto Y. Hamamoto Y. J Thorac Dis. 2018 Jun;10(Suppl 17):S2086-S2088. doi: 10.21037/jtd.2018.05.37. J Thorac Dis. 2018. PMID: 30023126 Free PMC article. No abstract available.

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.
Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, Hironaka S, Hara H, Satoh T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Kitagawa Y. Kudo T, et al. Lancet Oncol. 2017 May;18(5):631-639. doi: 10.1016/S1470-2045(17)30181-X. Epub 2017 Mar 15. Lancet Oncol. 2017. PMID: 28314688 Clinical Trial.

1. Global Burden of Disease Cancer C , Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524-48. 10.1001/jamaoncol.2016.5688 - DOI - PMC - PubMed
1. Selenko-Gebauer N, Majdic O, Szekeres A, et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 2003;170:3637-44. 10.4049/jimmunol.170.7.3637 - DOI - PubMed
1. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800. 10.1038/nm730 - DOI - PubMed
1. Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol 2015;6:561-9. - PMC - PubMed
1. Saeterdal I, Bjorheim J, Lislerud K, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001;98:13255-60. 10.1073/pnas.231326898 - DOI - PMC - PubMed